



MAKING CREXONT MORE ACCESSIBLE FOR
TRICARE AND VA BENEFICIARIES

CREXONT IS TIER 2 ON THE TRICARE UNIFORM AND VA NATIONAL FORMULARY

PATIENTS THAT ARE COVERED UNDER TRICARE AND THE VETERANS HEALTH ADMINISTRATION NOW HAVE AFFORDABLE ACCESS* TO CREXONT (CARBIDOPA AND LEVODOPA) EXTENDED-RELEASE CAPSULES TO HELP MANAGE THEIR TREATMENT NEEDS.



TRICARE FULFILLMENT OPTIONS FOR CREXONT:

\$38 FOR MAIL ORDER UP TO 90-DAY
PRESCRIPTION FOR ACTIVE DUTY

\$43 FOR UP TO 30-DAY PRESCRIPTION
AT RETAIL PHARMACY

\$0 FOR MILITARY TREATMENT FACILITY
ON-BASE OR ON-POST

VA FULFILLMENT OPTIONS FOR CREXONT:

\$33 FOR MAIL ORDER UP TO 90-DAY
PRESCRIPTION AT THE CENTRALIZED
MAIL-ORDER PHARMACY**

\$11 FOR UP TO 30-DAY PRESCRIPTION
AT A LOCAL VA MEDICAL CENTER
PHARMACY**



*Prior Authorization (PA) required: Patient has tried and failed generic controlled release formulation of carbidopa/levodopa; PA does not expire, i.e., no renewal required.

**VA Co-pays range from \$0 to \$11 per month, depending on several factors including the veteran's service-connected disability rating, income level, and other eligibility criteria determined by the U.S. Department of Veterans Affairs (VA).

CREXONT® is a registered trademark of Amneal Pharmaceuticals LLC.
© 2025 Amneal Pharmaceuticals LLC. All rights reserved. Printed in USA.

PP-ADP-CREX-US-0013 02/2025